Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: A retrospective two-dose comparative study

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 1, 2012, Pages 41-48

  Sasamoto, Yuzuru ^a   Oshima, Yusuke ^a   Miki, Atsuya ^a   Wakabayashi, Taku ^a   Song, Dan ^b   Matsushita, Kenji ^a   Hamasaki, Toshimitsu ^a   Nishida, Kohji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS NEOVASCULARIZATION; LOW DRUG DOSE; MALE; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; IRIS; IRIS DISEASES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856928331     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0059     Document Type: Article

References (40)

1. Sivak-Callcott, J.A., O'Day, D.M., Gass, J.D., and Tsai, J.C. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 108:1767-1776, 2001. (Pubitemid 32905930)
2. Allen, R.C., Bellows, A.R., Hutchinson, B.T., and Murphy, S.D. Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology 89:1181-1187, 1982. (Pubitemid 12003237)
3. Murphy, R.P., and Egbert, P.R. Regression of iris neo-vascularization following panretinal photocoagulation. Arch. Ophthalmol. 97:700-702, 1979. (Pubitemid 9135279)
4. Pavan, P.R., Folk, J.C., Weingeist, T.A., Hermsen, V.M., Watzke, R.C., and Montague, P.R. Diabetic rubeosis and pan-retinal photocoagulation. Arch. Ophthalmol. 101:882-884, 1983.
5. Tasman, W., Magargal, L.E., and Augsburger, J.J. Effects of argon laser photocoagulation on rubeosis iridis and angle neovascularization. Ophthalmology 87:400-402, 1980. (Pubitemid 10102644)
6. Tsai, J.C., Feuer, W.J., Parrish, R.K., 2nd, and Grajewski, A.L. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 102:887-892, 1995.
7. Wand, M., Dueker, D.K., Aiello, L.M., and Grant, W.M. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am. J. Oph-thalmol. 86:332-339, 1978. (Pubitemid 9063022)
8. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endo-thelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994. (Pubitemid 24356306)
9. Tripathi, R.C., Li, J., Tripathi, B.J., Chalam, K.V., and Ada-mis, A.P. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 105:232-237, 1998. (Pubitemid 28090825)
10. Adamis, A.P., Shima, D.T., Tolentino, M.J., et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114:66-71, 1996. (Pubitemid 26026196)
11. Tolentino, M.J., Miller, J.W., Gragoudas, E.S., et al. Vascular endothelial growth factor is sufficient to produce iris neo-vascularization and neovascular glaucoma in a nonhuman primate. Arch. Ophthalmol. 114:964-970, 1996. (Pubitemid 26271462)
12. Ferrara, N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab. Invest. 72:615-618, 1995.
13. Avery, R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352-354, 2006. (Pubitemid 44318195)
14. Iliev, M.E., Domig, D., Wolf-Schnurrbursch, U., Wolf, S., and Sarra, G.M. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am. J. Ophthalmol. 142:1054-1056, 2006. (Pubitemid 44853889)
15. Jonas, J.B., Spandau, U.H., and Schlichtenbrede, F. In-travitreal bevacizumab for filtering surgery. Ophthalmic. Res. 39:121-122, 2007.
16. Miki, A., Oshima, Y., Otori, Y., Kamei, M., and Tano, Y. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br. J. Oph-thalmol. 92:1431-1433, 2008.
17. Oshima, Y., Sakaguchi, H., Gomi, F., and Tano, Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic reti-nopathy. Am. J. Ophthalmol. 142:155-158, 2006.
18. Wakabayashi, T., Oshima, Y., Sakaguchi, H., et al. In-travitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571-1580, 2008.
19. Saito, Y., Higashide, T., Takeda, H., Ohkubo, S., and Sugiyama, K. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol. 88:96-102, 2010.
20. Sawada, O., Kawamura, H., Kakinoki, M., Sawada, T., and Ohji, M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch. Ophthalmol. 125: 1363-1366, 2007. (Pubitemid 47606601)
21. Marneros, A.G., Fan, J., Yokoyama, Y., et al. Vascular en-dothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 167:1451-1459, 2005. (Pubitemid 41541430)
22. Saint-Geniez, M., Kurihara, T., Sekiyama, E., Maldonado, A.E., and D'Amore, P.A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc. Natl. Acad. Sci. U.S.A. 106:18751-18756, 2009.
23. Jin, K.L., Mao, X.O., and Greenberg, D.A. Vascular endo-thelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. U.S.A. 97:10242-10247, 2000.
24. Nishijima, K., Ng, Y.S., Zhong, L., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to is-chemic injury. Am. J. Pathol. 171:53-67, 2007. (Pubitemid 47339226)
25. Sondell, M., Lundborg, G., and Kanje, M. Vascular endo-thelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19:5731-5740, 1999. (Pubitemid 29327910)
26. Yokoyama, K., Choshi, T., Kimoto, K., Shinoda, K., and Nakatsuka, K. Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol. 86:927-928, 2008.
27. Sabet-Peyman, E.J., Heussen, F.M., Thorne, J.E., Casparis, H., Patel, S.J., and Do, D.V. Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic. Surg. Lasers Imaging 40:316-318, 2009.
28. Lee, S.J., and Koh, H.J. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. J. Ocul. Pharmacol. Ther. 25:173-174, 2009.
29. Huang, Z.L., Lin, K.H., Lee, Y.C., Sheu, M.M., and Tsai, R.K. Acute vision loss after intravitreal injection of bevacizumab (Avastin) associated with ocular ischemic syndrome. Oph-thalmologica 224:86-89, 2009.
30. Grover, S., Gupta, S., Sharma, R., Brar, V.S., and Chalam, K.V. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neo-vascular glaucoma. Br. J. Ophthalmol. 93:273-274, 2009.
31. Matsuyama, K., Ogata, N., Jo, N., et al. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bev-acizumab. Jpn. J. Ophthalmol. 53:243-248, 2009.
32. Aiello, L.P., Brucker, A.J., Chang, S., et al. Evolving guidelines for intravitreous injections. Retina 24(5 Suppl):S3-S19, 2004. (Pubitemid 39391785)
33. Holladay, J.T. Proper method for calculating average visual acuity. J. Refract. Surg. 13:388-391, 1997. (Pubitemid 27369067)
34. Schulze-Bonsel, K., Feltgen, N., Burau, H., Hansen, L., and Bach, M. Visual acuities "hand motion" and "counting fingers" can be quantified with the Freiburg visual acuity test. Invest. Ophthalmol. Vis. Sci. 47:1236-1240, 2006. (Pubitemid 46768362)
35. Bakri, S.J., Snyder, M.R., Reid, J.M., Pulido, J.S., and Singh, R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-859, 2007. (Pubitemid 46635858)
36. Krohne, T.U., Eter, N., Holz, F.G., and Meyer, C.H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am. J. Ophthalmol. 146:508-512, 2008.
37. Beutel, J., Peters, S., Lü ke, M., et al. Bevacizumab Study Group. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. 88:103-109, 2010.
38. Ueta, T., Yanagi, Y., Tamaki, Y., and Yamaguchi, T. Cere-brovascular accidents in ranibizumab. Ophthalmology 116:362, 2009.
39. Stergiou, P.K., Symeonidis, C., and Dimitrakos, S.A. Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization. Acta Ophthalmol. 89:218-21, 2011.
40. Satio, Y., Higashide, T., Takeda, H., et al. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab. Am. J. Ophthalmol. 149:964-972, 2010.